Related to Bayer Schering Pharma Receives Chinese Approval for MS Drug and Signs Anticancer Deal with Micromet

• Bayer Nabs Global Rights to Algeta’s Late-Stage Radiopharmaceutical for Roughly $60.64M
  
• PerkinElmer Makes Two Acquisitions to Pad Diagnostics Business in Emerging Markets
  
• BioTime Sets Up Subsidiary in China to Develop Stem Cell Therapeutics
  
• Prodrug of Eisai’s Antifungal to Be Investigated in Chagas
  
• GSK Furthers Interest in China through Pediatric Vaccines JV with Initial $32M Investment
  
• Kinaxo to Help Bayer Predict Patient Response to Nexavar in AML Clinical Trial
  
• PPD to Spin Out Compound-Partnering Segment, Acquire Chinese CRO, and Invest $100M in Celtic Therapeutics
  
• Simcere Fortifies Stake in Chinese H1N1 Vaccine Firm to Over 50%
  
• Novartis to Invest $1.25B in Two New Facilities in China
  
• Novartis to Buy 85% of Chinese Vaccines Company for $125M
  
• Wanbang to Advance D-Pharm’s Late-Stage Stroke Therapy in China
  
• PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Sinovac Expands Vaccine Capabilities with New JV
  
• Pfizer and Crown Team Up to Develop Treatments for Asian Cancers
  
• Bayer Returns Commercial Rights Covering Human Thrombin Therapy to ZymoGenetics
  
• Meda In-Licenses Commercial Rights to EpiCept’s AML Therapy for $3M
  
• Acorda Obtains FDA Nod for Oral Drug that Improves Walking in MS Patients
  
• Lonza to Manufacture Micromet’s Blinatumomab BiTE Antibody